87703 20240116083604.0 doi 10.1016/j.atherosclerosis.2019.02.003 sideral 111291 ART-2019-111291 eng Perez-Calahorra, S. Universidad de Zaragoza (orcid)0000-0002-1894-1621 Effect of lipid-lowering treatment in cardiovascular disease prevalence in familial hypercholesterolemia 2019 Access copy available to the general public Unrestricted Background and aims: The impact on heterozygous familial hypercholesterolemia (HeFH) health led by high-intensity lipid-lowering therapy (HILLT) is unknown, and the question remains if there is still an unacceptably high residual risk to justify treatment with new lipid-lowering drugs. Methods: This observational, retrospective, multicenter, national study in Spain, whose information was obtained from a national dyslipemia registry, was designed to establish the current prevalence of cardiovascular disease (CVD) in HeFH and to define the impact of HILLT on CVD in this population. Odds were estimated using several logistic regression models with progressive adjustment. Results: 1958 HeFH, mean age 49.3 ± 14.3 years, were included in the analysis. At inclusion in the registry, 295 patients (15.1%) had suffered CVD and 164 (55.6%) had suffered the first event before the onset lipid-lowering treatment. Exposition to treatment associated more than ten times lower odds for CVD than in subjects naïve to treatment (OR 0.085, 95% CI 0.063–0.114, p < 0.001). A first CVD event after a mean treatment period of 9.1 ± 7.2 years occurred in 131 out of 1615 (8.1%) HeFH subjects, and 115 (87.8%) of them were on HILLT. Conclusions: Current prevalence of CVD among HeFH is one third of that reported before the statins era. Early initiation and prolonged lipid-lowering treatment was associated with a reduction in CVD. New cases of CVD, in spite of HILLT, appeared mostly among patients accumulating risk factors and probably they may be considered for further lipid-lowering drugs. info:eu-repo/grantAgreement/EUR/ISCII-ERDF/A way to make Europe info:eu-repo/grantAgreement/ES/MINECO/PI15-01983 info:eu-repo/semantics/openAccess by-nc-nd http://creativecommons.org/licenses/by-nc-nd/3.0/es/ 3.919 2019 PERIPHERAL VASCULAR DISEASE 16 / 65 = 0.246 2019 Q1 T1 CARDIAC & CARDIOVASCULAR SYSTEMS 42 / 138 = 0.304 2019 Q2 T1 1.515 2019 Cardiology and Cardiovascular Medicine 2019 Q1 info:eu-repo/semantics/article info:eu-repo/semantics/acceptedVersion Laclaustra, M. (orcid)0000-0003-3963-0846 Marco-Benedí, V. Lamiquiz-Moneo, I. Universidad de Zaragoza (orcid)0000-0002-9647-0108 Pedro-Botet, J. Plana, N. Sanchez-Hernandez, R.M. Amor, A.J. Almagro, F. Fuentes, F. Suarez-Tembra, M. Civeira, F. Universidad de Zaragoza (orcid)0000-0001-7043-0952 1006 255 Universidad de Zaragoza Dpto. Fisiatría y Enfermería Área Enfermería 1003 027 Universidad de Zaragoza Dpto. Anatom.Histolog.Humanas Area Anatom.Embriol.Humana 1007 610 Universidad de Zaragoza Dpto. Medicina, Psiqu. y Derm. Area Medicina 284 (2019), 245-252 Atherosclerosis Atherosclerosis 0021-9150 1333893 http://zaguan.unizar.es/record/87703/files/texto_completo.pdf Postprint 246585 http://zaguan.unizar.es/record/87703/files/texto_completo.jpg?subformat=icon icon Postprint oai:zaguan.unizar.es:87703 articulos driver 2024-01-16-08:32:26 ARTICLE